PLATO trial

PLATO trial
Name	PLATO trial
Acronym	PLATO
Phase	Phase III
Design	Randomized, double-blind, multinational
Participants	~18,624
Interventions	Ticagrelor vs Clopidogrel
Primary outcome	Composite of cardiovascular death, myocardial infarction, or stroke
Start date	2006
Completion date	2009
Sponsor	AstraZeneca

PLATO trial

The PLATO trial was a large randomized, double-blind, multinational clinical study comparing the P2Y12 receptor antagonist ticagrelor with the thienopyridine clopidogrel for prevention of ischemic events in patients with acute coronary syndromes. Conducted across hospitals and research centers in multiple countries, the trial enrolled approximately 18,624 participants and reported differences in efficacy and safety outcomes that influenced practice guidelines and regulatory decisions. The study intersected with regulatory agencies, professional societies, and industry stakeholders, prompting extensive discussion in cardiology, pharmacology, and health policy circles.

Background

The trial was conceived amid ongoing debate about optimal antiplatelet therapy following acute coronary syndromes, with precedent trials such as CURE trial, COMMIT trial, TRITON-TIMI 38 and CHARISMA trial shaping the landscape. Development of ticagrelor by AstraZeneca followed earlier commercialization of clopidogrel by Sanofi and Bristol-Myers Squibb; contemporaneous regulatory reviews involved the European Medicines Agency and the U.S. Food and Drug Administration. Principal investigators and steering committees drew expertise from academic centers affiliated with institutions like Harvard Medical School, University of Oxford, Imperial College London, and McMaster University. The trial design reflected guidance from professional societies including the European Society of Cardiology and the American College of Cardiology.

Methods

PLATO used a randomized, double-blind, active-controlled design enrolling subjects with ST-elevation and non–ST-elevation acute coronary syndromes presenting to participating centers in regions such as North America, Europe, Asia-Pacific, and Latin America. Randomization allocated participants to ticagrelor or clopidogrel with concomitant use of aspirin per local practice; the protocol specified dose regimens, stratification factors, and event-adjudication by independent committees tied to academic endpoints committees at centers like Duke University and Cleveland Clinic. Primary and secondary endpoints mirrored those used in earlier trials including composite ischemic outcomes and all-cause mortality; statistical plans referenced methods from biostatistical frameworks developed at Johns Hopkins University and University of Pennsylvania. Data monitoring involved an independent data and safety monitoring board with oversight comparable to processes used in trials such as PLATO-era cardiovascular studies.

Results

The primary efficacy analysis reported a statistically significant reduction in the composite endpoint of cardiovascular death, myocardial infarction, or stroke with ticagrelor versus clopidogrel, driven by reductions in myocardial infarction and cardiovascular death. Numerically, the trial reported hazard ratios and confidence intervals that were discussed in publications and presentations at meetings including the European Society of Cardiology Congress and the American Heart Association Scientific Sessions. Subgroup analyses examined interactions across clinical settings represented by trials like TRITON-TIMI 38 and populations from registries such as GRACE registry and CRUSADE registry. Regional differences, particularly in results from investigators and centers in North America versus other regions, were highlighted in statistical appendices and regulatory briefings to agencies including the European Medicines Agency.

Safety and adverse events

Safety analyses reported higher rates of non–CABG-related major bleeding with ticagrelor in certain definitions, while CABG-related bleeding rates differed between groups. Adverse-event profiles included dyspnea and bradyarrhythmias, which were discussed in pharmacovigilance reports submitted to agencies like the U.S. Food and Drug Administration and monitored by post-marketing surveillance initiatives linked to organizations such as the World Health Organization. Serious adverse events prompted dialog among clinicians at institutions like Massachusetts General Hospital and Mayo Clinic, and informed updates to product labeling endorsed by regulatory bodies including the European Medicines Agency and national competent authorities.

Interpretation and impact

Findings from the trial influenced clinical practice guidelines from the European Society of Cardiology and the American College of Cardiology/American Heart Association, shaping recommendations for antiplatelet selection after acute coronary syndromes and percutaneous coronary intervention procedures performed in centers such as St Thomas' Hospital and Royal Brompton Hospital. Adoption of ticagrelor affected formulary decisions at healthcare systems including NHS England and large academic hospitals, and informed cost-effectiveness analyses undertaken by health technology assessment bodies like National Institute for Health and Care Excellence and Institute for Clinical and Economic Review. The trial’s results also guided subsequent trials and registries, including comparative effectiveness work and mechanistic studies at institutions like Karolinska Institutet and University of Toronto.

Criticisms and controversies

The trial generated controversy around regional treatment effect heterogeneity, interpretation of mortality differences, and sponsor interactions with investigators and regulators. Debates referenced prior trial controversies such as concerns raised in TRITON-TIMI 38 and discussions involving litigation and transparency seen in cases with other pharmaceutical programs. Critics pointed to baseline imbalances, subgroup multiplicity, and prespecified analytical choices; these topics were debated in editorials in journals associated with publishers like The Lancet, New England Journal of Medicine, and European Heart Journal. Regulatory discussions involved exchanges between AstraZeneca and agencies including the U.S. Food and Drug Administration, and post-hoc analyses and independent meta-analyses by academic consortia at Stanford University and Yale University sought to clarify unresolved questions.

Category:Cardiology clinical trials